BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010;59:521-30. [PMID: 20332524 DOI: 10.1136/gut.2009.186528] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Trivedi PJ, Weston CJ, Webb GJ, Newsome PN, Hirschfield GM, Adams DH. Serum alkaline phosphatase in multidrug resistance 2 (Mdr2(-/-) ) knockout mice is strain specific. Hepatology 2016;63:346. [PMID: 25930031 DOI: 10.1002/hep.27874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Tian M, Zhang X, Wang L, Li Y. Curcumin Induces ABCA1 Expression and Apolipoprotein A-I-Mediated Cholesterol Transmembrane in the Chronic Cerebral Hypoperfusion Aging Rats. Am J Chin Med 2013;41:1027-42. [DOI: 10.1142/s0192415x13500699] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
3 Yan C, Koda S, Wu J, Zhang BB, Yu Q, Netea MG, Tang RX, Zheng KY. Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target. Hepatology 2020;72:1838-50. [PMID: 32463941 DOI: 10.1002/hep.31395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Yin W, Zhang X, Li Y. Protective effects of curcumin in APPswe transfected SH-SY5Y cells. Neural Regen Res 2012;7:405-12. [PMID: 25774181 DOI: 10.3969/j.issn.1673-5374.2012.06.001] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 An S, Jang E, Lee JH. Preclinical Evidence of Curcuma longa and Its Noncurcuminoid Constituents against Hepatobiliary Diseases: A Review. Evid Based Complement Alternat Med 2020;2020:8761435. [PMID: 32802138 DOI: 10.1155/2020/8761435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ran Z, Zhang Y, Wen X, Ma J. Curcumin inhibits high glucose‑induced inflammatory injury in human retinal pigment epithelial cells through the ROS‑PI3K/AKT/mTOR signaling pathway. Mol Med Rep 2019;19:1024-31. [PMID: 30569107 DOI: 10.3892/mmr.2018.9749] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
7 Zhang Z, Li K. Curcumin attenuates high glucose-induced inflammatory injury through the reactive oxygen species-phosphoinositide 3-kinase/protein kinase B-nuclear factor-κB signaling pathway in rat thoracic aorta endothelial cells. J Diabetes Investig 2018;9:731-40. [PMID: 29080256 DOI: 10.1111/jdi.12767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
8 Fuchs CD, Paumgartner G, Mlitz V, Kunczer V, Halilbasic E, Leditznig N, Wahlström A, Ståhlman M, Thüringer A, Kashofer K, Stojakovic T, Marschall HU, Trauner M. Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids. Gut 2018;67:1683-91. [PMID: 29636383 DOI: 10.1136/gutjnl-2017-314553] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
9 Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Kandimalla R, Kuruva CS. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease. J Investig Med 2016;64:1220-34. [PMID: 27521081 DOI: 10.1136/jim-2016-000240] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
10 Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol. 2013;59:571-582. [PMID: 23603668 DOI: 10.1016/j.jhep.2013.03.015] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 8.6] [Reference Citation Analysis]
11 Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Tonk S, Kuruva CS, Bhatti JS, Kandimalla R, Vijayan M, Kumar S, Wang R, Pradeepkiran JA, Ogunmokun G, Thamarai K, Quesada K, Boles A, Reddy AP. Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease. J Alzheimers Dis 2018;61:843-66. [PMID: 29332042 DOI: 10.3233/JAD-170512] [Cited by in Crossref: 98] [Cited by in F6Publishing: 44] [Article Influence: 32.7] [Reference Citation Analysis]
12 Khamphaya T, Chansela P, Piyachaturawat P, Suksamrarn A, Nathanson MH, Weerachayaphorn J. Effects of andrographolide on intrahepatic cholestasis induced by alpha-naphthylisothiocyanate in rats. European Journal of Pharmacology 2016;789:254-64. [DOI: 10.1016/j.ejphar.2016.07.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zhao X, Xu Y, Zhao Q, Chen C, Liu A, Huang Z. Curcumin exerts antinociceptive effects in a mouse model of neuropathic pain: Descending monoamine system and opioid receptors are differentially involved. Neuropharmacology 2012;62:843-54. [DOI: 10.1016/j.neuropharm.2011.08.050] [Cited by in Crossref: 105] [Cited by in F6Publishing: 100] [Article Influence: 10.5] [Reference Citation Analysis]
14 Heritage M, Jaskowski L, Bridle K, Campbell C, Briskey D, Britton L, Fletcher L, Vitetta L, Subramaniam VN, Crawford D. Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice. World J Gastrointest Pathophysiol 2017; 8(2): 67-76 [PMID: 28573069 DOI: 10.4291/wjgp.v8.i2.67] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO-3 output. Hepatology. 2011;54:1303-1312. [PMID: 22006858 DOI: 10.1002/hep.24537] [Cited by in Crossref: 149] [Cited by in F6Publishing: 131] [Article Influence: 13.5] [Reference Citation Analysis]
16 Hu RW, Carey EJ, Lindor KD, Tabibian JH. Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications. Ann Hepatol. 2017;16:835-841. [PMID: 29055920 DOI: 10.5604/01.3001.0010.5273] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
17 Sancho P, Mainez J, Crosas-Molist E, Roncero C, Fernández-Rodriguez CM, Pinedo F, Huber H, Eferl R, Mikulits W, Fabregat I. NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS One. 2012;7:e45285. [PMID: 23049784 DOI: 10.1371/journal.pone.0045285] [Cited by in Crossref: 99] [Cited by in F6Publishing: 97] [Article Influence: 9.9] [Reference Citation Analysis]
18 Karin D, Koyama Y, Brenner D, Kisseleva T. The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation 2016;92:84-92. [PMID: 27591095 DOI: 10.1016/j.diff.2016.07.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
19 Uğuz AC, Öz A, Nazıroğlu M. Curcumin inhibits apoptosis by regulating intracellular calcium release, reactive oxygen species and mitochondrial depolarization levels in SH-SY5Y neuronal cells. J Recept Signal Transduct Res 2016;36:395-401. [PMID: 26608462 DOI: 10.3109/10799893.2015.1108337] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
20 Wen M, Liu Y, Chen R, He P, Wu F, Li R, Lin Y. Geniposide suppresses liver injury in a mouse model of DDC-induced sclerosing cholangitis. Phytother Res 2021;35:3799-811. [PMID: 33763888 DOI: 10.1002/ptr.7086] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wen J. Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease. Clin Transl Sci 2011;4:460-5. [PMID: 22212229 DOI: 10.1111/j.1752-8062.2011.00306.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
22 Yang F, Tang X, Ding L, Zhou Y, Yang Q, Gong J, Wang G, Wang Z, Yang L. Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation. Sci Rep. 2016;6:33052. [PMID: 27624003 DOI: 10.1038/srep33052] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
23 Wan Y, Meng F, Wu N, Zhou T, Venter J, Francis H, Kennedy L, Glaser T, Bernuzzi F, Invernizzi P, Glaser S, Huang Q, Alpini G. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Hepatology. 2017;66:528-541. [PMID: 28256736 DOI: 10.1002/hep.29138] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
24 Baghdasaryan A, Fuchs CD, Österreicher CH, Lemberger UJ, Halilbasic E, Påhlman I, Graffner H, Krones E, Fickert P, Wahlström A, Ståhlman M, Paumgartner G, Marschall HU, Trauner M. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol 2016;64:674-81. [PMID: 26529078 DOI: 10.1016/j.jhep.2015.10.024] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 11.7] [Reference Citation Analysis]
25 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Reference Citation Analysis]
26 Meng Z, Yu XH, Chen J, Li L, Li S. Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR-γ activation. Acta Pharmacol Sin 2014;35:1247-56. [PMID: 25132338 DOI: 10.1038/aps.2014.63] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
27 Nabavi SF, Daglia M, Moghaddam AH, Habtemariam S, Nabavi SM. Curcumin and Liver Disease: from Chemistry to Medicine: Curcumin and liver disease…. Comprehensive Reviews in Food Science and Food Safety 2014;13:62-77. [DOI: 10.1111/1541-4337.12047] [Cited by in Crossref: 97] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
28 Firrincieli D, Zuniga S, Poupon R, Housset C, Chignard N. Role of nuclear receptors in the biliary epithelium. Dig Dis 2011;29:52-7. [PMID: 21691105 DOI: 10.1159/000324129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
29 Razavi BM, Ghasemzadeh Rahbardar M, Hosseinzadeh H. A review of therapeutic potentials of turmeric (Curcuma longa) and its active constituent, curcumin, on inflammatory disorders, pain, and their related patents. Phytother Res 2021. [PMID: 34312922 DOI: 10.1002/ptr.7224] [Reference Citation Analysis]
30 Rudraiah S, Zhang X, Wang L. Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet? Annu Rev Pharmacol Toxicol. 2016;56:605-626. [PMID: 26738480 DOI: 10.1146/annurev-pharmtox-010715-103209] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
31 Pollheimer MJ, Fickert P. Animal Models in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinic Rev Allerg Immunol 2015;48:207-17. [DOI: 10.1007/s12016-014-8442-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
32 Zhang X, Yin WK, Shi XD, Li Y. Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells. Eur J Pharm Sci 2011;42:540-6. [PMID: 21352912 DOI: 10.1016/j.ejps.2011.02.009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 6.9] [Reference Citation Analysis]
33 Xu J, Liu X, Koyama Y, Wang P, Lan T, Kim IG, Kim IH, Ma HY, Kisseleva T. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front Pharmacol 2014;5:167. [PMID: 25100997 DOI: 10.3389/fphar.2014.00167] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 6.5] [Reference Citation Analysis]
34 Kennedy LL, Meng F, Venter JK, Zhou T, Karstens WA, Hargrove LA, Wu N, Kyritsi K, Greene J, Invernizzi P, Bernuzzi F, Glaser SS, Francis HL, Alpini G. Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. Lab Invest 2016;96:1256-67. [PMID: 27775690 DOI: 10.1038/labinvest.2016.112] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
35 Rajasekaran SA. Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol 2011; 2(1): 1-14 [PMID: 21607160 DOI: 10.4291/wjgp.v2.i1.1] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
36 Fernández-Ramos D, Fernández-Tussy P, Lopitz-Otsoa F, Gutiérrez-de-Juan V, Navasa N, Barbier-Torres L, Zubiete-Franco I, Simón J, Fernández AF, Arbelaiz A, Aransay AM, Lavín JL, Beraza N, Perugorria MJ, Banales JM, Villa E, Fraga MF, Anguita J, Avila MA, Berasain C, Iruzibieta P, Crespo J, Lu SC, Varela-Rey M, Mato JM, Delgado TC, Martínez-Chantar ML. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. Cell Death Dis 2018;9:958. [PMID: 30237481 DOI: 10.1038/s41419-018-1014-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
37 Latasa MU, Gil-Puig C, Fernández-Barrena MG, Rodríguez-Ortigosa CM, Banales JM, Urtasun R, Goñi S, Méndez M, Arcelus S, Juanarena N, Recio JA, Lotersztajn S, Prieto J, Berasain C, Corrales FJ, Lecanda J, Avila MA. Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice. PLoS One 2010;5:e15690. [PMID: 21209952 DOI: 10.1371/journal.pone.0015690] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
38 Fickert P, Pollheimer MJ, Österreicher CH, Trauner M. Animal Models of Cholestasis. Animal Models for the Study of Human Disease. Elsevier; 2013. pp. 331-49. [DOI: 10.1016/b978-0-12-415894-8.00015-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
39 Balachandar S, Katyal A. Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy. Eur J Clin Microbiol Infect Dis 2011;30:483-98. [PMID: 21140187 DOI: 10.1007/s10096-010-1122-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
40 Halilbasic E, Baghdasaryan A, Trauner M. Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis. 2013;17:161-189. [PMID: 23540496 DOI: 10.1016/j.cld.2012.12.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
41 Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC? - "it's hard to be a PSC model!". Clin Res Hepatol Gastroenterol. 2011;35:792-804. [PMID: 21703962 DOI: 10.1016/j.clinre.2011.04.014] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
42 Miyao M, Ozeki M, Abiru H, Manabe S, Kotani H, Tsuruyama T, Tamaki K. Bile canalicular abnormalities in the early phase of a mouse model of sclerosing cholangitis. Dig Liver Dis 2013;45:216-25. [PMID: 23107486 DOI: 10.1016/j.dld.2012.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
43 Bridle KR, Sobbe AL, de Guzman CE, Santrampurwala N, Jaskowski LA, Clouston AD, Campbell CM, Nathan Subramaniam V, Crawford DH. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2−/− mice. Liver Int 2015;35:1451-63. [DOI: 10.1111/liv.12494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
44 Fuji H, Miller G, Nishio T, Koyama Y, Lam K, Zhang V, Loomba R, Brenner D, Kisseleva T. The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis. Front Mol Biosci 2021;8:790032. [PMID: 34966784 DOI: 10.3389/fmolb.2021.790032] [Reference Citation Analysis]
45 Anggakusuma , Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJ, Bankwitz D, Steinmann J. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut. 2014;63:1137-1149. [PMID: 23903236 DOI: 10.1136/gutjnl-2012-304299] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
46 Baghdasaryan A, Chiba P, Trauner M. Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med. 2014;37:57-76. [PMID: 24333169 DOI: 10.1016/j.mam.2013.12.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
47 Gonzalez-Sanchez E, El Mourabit H, Jager M, Clavel M, Moog S, Vaquero J, Ledent T, Cadoret A, Gautheron J, Fouassier L, Wendum D, Chignard N, Housset C. Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice. Biochim Biophys Acta Mol Basis Dis 2021;1867:166067. [PMID: 33418034 DOI: 10.1016/j.bbadis.2020.166067] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology. 2011;140:1120-1125.e1-12. [PMID: 21334334 DOI: 10.1053/j.gastro.2011.02.044] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 6.6] [Reference Citation Analysis]
49 Fumia A, Cicero N, Gitto M, Nicosia N, Alesci A. Role of nutraceuticals on neurodegenerative diseases: neuroprotective and immunomodulant activity. Nat Prod Res 2021;:1-18. [PMID: 34963389 DOI: 10.1080/14786419.2021.2020265] [Reference Citation Analysis]
50 Koyama Y, Wang P, Liang S, Iwaisako K, Liu X, Xu J, Zhang M, Sun M, Cong M, Karin D, Taura K, Benner C, Heinz S, Bera T, Brenner DA, Kisseleva T. Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis. J Clin Invest 2017;127:1254-70. [PMID: 28287406 DOI: 10.1172/JCI88845] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
51 Jones H, Hargrove L, Kennedy L, Meng F, Graf-Eaton A, Owens J, Alpini G, Johnson C, Bernuzzi F, Demieville J, DeMorrow S, Invernizzi P, Francis H. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice. Hepatology 2016;64:1202-16. [PMID: 27351144 DOI: 10.1002/hep.28704] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
52 Ceccherini E, Cecchettini A, Morales MA, Rocchiccioli S. The Potentiality of Herbal Remedies in Primary Sclerosing Cholangitis: From In Vitro to Clinical Studies. Front Pharmacol 2020;11:813. [PMID: 32587513 DOI: 10.3389/fphar.2020.00813] [Reference Citation Analysis]
53 Wu N, Meng F, Invernizzi P, Bernuzzi F, Venter J, Standeford H, Onori P, Marzioni M, Alvaro D, Franchitto A, Gaudio E, Glaser S, Alpini G. The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-β1 biliary secretion in mice. Hepatology 2016;64:865-79. [PMID: 27115285 DOI: 10.1002/hep.28622] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 8.2] [Reference Citation Analysis]
54 Eaton JE, Nelson KM, Gossard AA, Carey EJ, Tabibian JH, Lindor KD, LaRusso NF. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. Scand J Gastroenterol 2019;54:633-9. [PMID: 31131678 DOI: 10.1080/00365521.2019.1611917] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]